Calamos Advisors LLC trimmed its stake in shares of Teleflex Incorporated (NYSE:TFX) by 40.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 26,795 shares of the medical technology company’s stock after selling 18,455 shares during the period. Calamos Advisors LLC’s holdings in Teleflex were worth $9,104,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of TFX. BlackRock Inc. lifted its position in Teleflex by 6.9% during the second quarter. BlackRock Inc. now owns 4,044,235 shares of the medical technology company’s stock valued at $1,339,247,000 after purchasing an additional 259,880 shares during the last quarter. Invesco Ltd. lifted its position in Teleflex by 29.3% during the second quarter. Invesco Ltd. now owns 870,117 shares of the medical technology company’s stock valued at $288,139,000 after purchasing an additional 197,426 shares during the last quarter. Marshall Wace LLP lifted its position in Teleflex by 26.7% during the second quarter. Marshall Wace LLP now owns 756,383 shares of the medical technology company’s stock valued at $250,476,000 after purchasing an additional 159,606 shares during the last quarter. Point72 Asset Management L.P. lifted its position in Teleflex by 162.8% during the second quarter. Point72 Asset Management L.P. now owns 233,638 shares of the medical technology company’s stock valued at $77,369,000 after purchasing an additional 144,730 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its position in Teleflex by 423.7% during the second quarter. Nuveen Asset Management LLC now owns 146,358 shares of the medical technology company’s stock valued at $48,466,000 after purchasing an additional 118,410 shares during the last quarter. 90.49% of the stock is owned by institutional investors.
In other news, CFO Thomas E. Powell sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $328.44, for a total value of $2,463,300.00. Following the completion of the sale, the chief financial officer now owns 17,539 shares in the company, valued at approximately $5,760,509.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Benson Smith sold 8,500 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $340.00, for a total transaction of $2,890,000.00. Following the completion of the sale, the director now owns 57,309 shares of the company’s stock, valued at approximately $19,485,060. The disclosure for this sale can be found here. Insiders sold a total of 41,104 shares of company stock valued at $13,993,223 in the last 90 days. Company insiders own 2.36% of the company’s stock.
Teleflex stock opened at $322.42 on Wednesday. The firm has a 50-day moving average price of $336.00 and a 200-day moving average price of $325.90. The firm has a market capitalization of $15.18 billion, a PE ratio of 32.57, a price-to-earnings-growth ratio of 2.13 and a beta of 0.98. The company has a current ratio of 2.52, a quick ratio of 1.59 and a debt-to-equity ratio of 0.82. Teleflex Incorporated has a 12-month low of $226.02 and a 12-month high of $373.90.
Teleflex (NYSE:TFX) last released its earnings results on Thursday, August 1st. The medical technology company reported $2.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.59 by $0.07. The firm had revenue of $652.50 million during the quarter, compared to analyst estimates of $637.06 million. Teleflex had a net margin of 10.78% and a return on equity of 18.57%. The business’s revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the business earned $2.47 EPS. As a group, sell-side analysts predict that Teleflex Incorporated will post 11.03 earnings per share for the current fiscal year.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Recommended Story: What is the Dividend Aristocrat Index?
Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.